Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell P Levesque

Showing results (11-20 of 203) with videos related to

Pageof 21
Sort By:
Frontiers in Oncology|June 14, 2018
Melanoma Immunotherapy: Next-Generation BiomarkersSabrina A Hogan, Mitchell P Levesque, Phil F Cheng
Current Opinion in Oncology|February 4, 2015
Curing advanced melanoma by 2025Reinhard Dummer, Simone M Goldinger, Verena Paulitschke, et al.
Expert Opinion on Investigational Drugs|March 8, 2012
Sorafenib in melanomaJoanna Mangana, Mitchell P Levesque, Maria B Karpova, et al.
Plos Genetics|November 14, 2009
Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermisSven Reischauer, Mitchell P Levesque, Christiane Nüsslein-Volhard, et al.
Expert Opinion on Pharmacotherapy|January 27, 2022
Advances in the drug management of basal cell carcinomaEgle Ramelyte, Gaetana Restivo, Maria Mannino, et al.
Experimental Dermatology|May 16, 2015
Melanoma's next top model, it is in the airDaniel S Widmer, Ossia M Eichhoff, Reinhard Dummer, et al.
Zebrafish|March 7, 2013
New tools for the identification of developmentally regulated enhancer regions in embryonic and adult zebrafishMitchell P Levesque, Jana Krauss, Carla Koehler, et al.
The Journal of Investigative Dermatology|April 16, 2014
To B-(RAF) or not to beReinhard Dummer, Simone M Goldinger, Daniel Widmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2012
Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapySima Rozati, Lukas Naef, Mitchell P Levesque, et al.
Current Opinion in Oncology|January 8, 2016
Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanomaVerena Paulitschke, Ossia Eichhoff, Phil F Cheng, et al.
Pageof 21

Showing results (11-20 of 203) with videos related to

Sort By:
Pageof 21
Frontiers in Oncology|June 14, 2018
Melanoma Immunotherapy: Next-Generation BiomarkersSabrina A Hogan, Mitchell P Levesque, Phil F Cheng
Current Opinion in Oncology|February 4, 2015
Curing advanced melanoma by 2025Reinhard Dummer, Simone M Goldinger, Verena Paulitschke, et al.
Expert Opinion on Investigational Drugs|March 8, 2012
Sorafenib in melanomaJoanna Mangana, Mitchell P Levesque, Maria B Karpova, et al.
Plos Genetics|November 14, 2009
Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermisSven Reischauer, Mitchell P Levesque, Christiane Nüsslein-Volhard, et al.
Expert Opinion on Pharmacotherapy|January 27, 2022
Advances in the drug management of basal cell carcinomaEgle Ramelyte, Gaetana Restivo, Maria Mannino, et al.
Experimental Dermatology|May 16, 2015
Melanoma's next top model, it is in the airDaniel S Widmer, Ossia M Eichhoff, Reinhard Dummer, et al.
Zebrafish|March 7, 2013
New tools for the identification of developmentally regulated enhancer regions in embryonic and adult zebrafishMitchell P Levesque, Jana Krauss, Carla Koehler, et al.
The Journal of Investigative Dermatology|April 16, 2014
To B-(RAF) or not to beReinhard Dummer, Simone M Goldinger, Daniel Widmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2012
Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapySima Rozati, Lukas Naef, Mitchell P Levesque, et al.
Current Opinion in Oncology|January 8, 2016
Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanomaVerena Paulitschke, Ossia Eichhoff, Phil F Cheng, et al.
Pageof 21